The inflammasome activates caspase-1 and the release of interleukin-1β (IL-1β) and IL-18, and several inflammasomes protect against intestinal inflammation and colitis-associated colon cancer (CAC) in animal models. The absent in melanoma 2 (AIM2) inflammasome is activated by double-stranded DNA, and AIM2 expression is reduced in several types of cancer, but the mechanism by which AIM2 restricts tumor growth remains unclear. We found that Aim2-deficient mice had greater tumor load than Asc-deficient mice in the azoxymethane/dextran sodium sulfate (AOM/DSS) model of colorectal cancer. Tumor burden was also higher in Aim2 -/-/Apc Min/+ than in APC Min/+ mice. The effects of AIM2 on CAC were independent of inflammasome activation and IL-1β and were primarily mediated by a non-bone marrow source of AIM2. In resting cells, AIM2 physically interacted with and limited activation of DNA-dependent protein kinase (DNA-PK), a PI3K-related family member that promotes Akt phosphorylation, whereas loss of AIM2 promoted DNA-PK-mediated Akt activation. AIM2 reduced Akt activation and tumor burden in colorectal cancer models, while an Akt inhibitor reduced tumor load in Aim2 -/-mice. These findings suggest that Akt inhibitors could be used to treat AIM2-deficient human cancers.
Inflammasome-independent role of AIM2 in suppressing colon tumorigenesis via DNA-PK and Akt (BMDM) failed to produce IL-1b following LPS priming and poly(dA:dT) stimulation (Supplementary Fig. 1b ). This is identical to what is observed with other strains of Aim2 -/-mice 15, 16 . Aim2 -/-mice did not display alterations in immune cell frequencies or numbers of lymphoid organs (Supplementary Fig. 2 ). To study the role of AIM2 in CAC, wild-type, Aim2 -/-and Asc -/-mice were intraperitoneally (i.p.) injected with azoxymethane (AOM) and then treated with three rounds of 3% dextran sodium sulfate (DSS) in drinking water 24 (Fig. 1a) . This model has been used to show the protective effect of multiple inflammasome components, including in restricting tumorigenesis during colitis-associated and sporadic colon cancer through suppression of Akt, a master regulator of cellular survival.
RESULTS

AIM2 does not affect inflammation and inflammasome activation in colitis models
To assess the role of AIM2 in CAC, we generated Aim2-deficient mice (termed Aim2 -/-) on the C57BL/6 genetic background ( Supplementary  Fig. 1a) , Asc -/-(n = 11) and wild-type (n = 30) mice following induction of CAC using AOM/DSS. Mock wild-type animals (n = 10) received a single i.p. injection of AOM and were given regular drinking water instead of DSS. Error bars, s.e.m. (e,f) H&E staining of colons from AOM/DSS-treated wild-type, Aim2 -/-and Asc -/-mice (e) and semiquantitative scoring of inflammation in colons from AOM/ DSS-treated wild-type and Aim2 -/-mice (f) (n = 6 for WT AOM/mock and Aim2 -/-AOM/DSS, and n = 5 for WT AOM/DSS and Aim2 -/-AOM/mock). Images were taken at 200× magnification; scale bars, 100 mm. (g,h) Inflammatory cytokine mRNA (AU, arbitrary units) (n = 3 for WT AOM/mock and Aim2 -/-AOM/mock, and n = 6 for WT AOM/DSS and Aim2 -/-AOM/DSS) (g) and protein expression in wild-type and Aim2 -/-colons (h) (n = 5 for WT AOM/mock and Aim2 -/-AOM/mock, n = 10 for WT AOM/DSS and n = 8 for Aim2 -/-AOM/DSS). (i,j) Caspase-1 activation in wild-type and Aim2 -/-colons (i) and IL-1b and IL-18 production in wild-type, Aim2 -/-and Asc -/-colons (j) (n = 5 for WT AOM/mock, Aim2 -/-AOM/mock and Asc -/-AOM/mock, and n = 10 for WT AOM/DSS, n = 8 for Aim2 -/-AOM/DSS and n = 5 for Asc -/-AOM/DSS). Error bars, s.e.m. ns, not significant; *P < 0.05, **P < 0.01,***P < 0.001; b,d,j, one-way ANOVA (Tukey's multiple-comparisons test); c, log-rank test.
polyp formation to a lesser extent than Aim2 deficiency, but did increase inflammation [5] [6] [7] . Because Aim2 -/-colon explants exhibited a slight, but statistically nonsignificant, increase in IL-1b production (Fig. 1j) , and IL-1b can promote tumorigenesis (reviewed in ref. 26 ), we generated Aim2 -/-/ Il1b -/-doubly deficient mice to determine whether IL-1b was responsible for the increased CAC in Aim2 -/-mice. Consistent with a previous report using mice lacking the IL-1b receptor during CAC 9 , AOM/DSS-treated Il1b -/-mice had numbers of colon polyps and tumor loads similar to those of wild-type mice (Fig. 2f) . However, Aim2 -/-/Il1b -/-and Aim2 -/-mice did not differ in terms of colon polyp numbers and tumor load (Fig. 2f) , indicating that IL-1b was not responsible for the increased tumorigenesis in Aim2 -/-mice. Thus, loss of AIM2 promoted tumorigenesis through a mechanism distinct from inflammasome regulation.
A non-bone marrow source of AIM2 protects against precancerous polyp formation We next determined the cellular source responsible for the enhanced tumorigenesis in the absence of AIM2 by generating radiation bone marrow-chimeric mice. Wild-type and Aim2 -/-mice were exposed to whole-body irradiation (8 Gy) to deplete the hematopoietic-progenitor compartment. Irradiated recipients were then reconstituted with either wild-type or Aim2 -/-bone marrow, and CAC was induced using AOM/ DSS. Wild-type mice reconstituted with Aim2 -/-bone marrow (Aim2 -/->WT) exhibited a trend of increased tumor size and burden as compared to wild-type control mice (WT>WT), although it did not reach statistical significance. An additional statistical analysis by t-test showed that the polyp size was significantly larger in Aim2 -/->WT (P = 0.0273) than in WT>WT mice, but the tumor load was not different (P = 0.073). By contrast, Aim2 -/-recipient mice reconstituted with wild-type bone marrow (WT>Aim2 -/-) were indistinguishable from Aim2 -/-control mice (Aim2 -/->Aim2 -/-) and had increased colon polyp numbers and tumor loads as compared to WT>WT controls (Fig. 2g) . These results suggest that Aim2 expression in radioresistant, non-bone marrow cells was primarily associated with the restriction of tumorigenesis during CAC. Because AIM2 suppressed colon tumorigenesis without affecting inflammasome function or limiting inflammation, and AIM2 has been implicated in human colon cancer [18] [19] [20] , we hypothesized that AIM2 would perform a similar protective role in a non-colitis-driven spontaneous model of colon cancer. To address this hypothesis, we generated Aim2 -/-mice that contain a heterozygous mutation in the adenomatous polyposis coli (Apc) gene (Aim2 -/-/Apc Min/+ ). Mutations in human APC are responsible for the hereditary form of colon cancer known as familial adenomatous polyposis (FAP), and mice with this mutation develop spontaneous intestinal, and to a lesser extent colorectal, tumors 27, 28 . Aim2 -/-/Apc Min/+ doubly deficient mice had greater numbers of colon tumors and higher tumor loads than singly deficient Apc Min/+ mice, the majority of which only had 0 or 1 colon polyp as previously described 27, 28 (Fig. 2h) , demonstrating that AIM2 also restricts sporadic colon tumorigenesis.
AIM2 inhibits Akt activation to restrict tumorigenesis
To explore the mechanism by which AIM2 impacts tumorigenesis, we explored multiple pathways that might be affected in Aim2 -/-colon tissue and cells. Loss of AIM2 in colorectal cancer lines has been associated with reduced HLA-DRA and HLA-DRB expression in vitro 29 , which could dampen antitumor immunity. However, I-Ab mRNA levels in wild-type and Aim2 -/-colon polyps or adjacent tissue did not differ ( Supplementary  Fig. 7a ). Mitogen-activated protein kinase (MAPK) pathways are major regulators of cellular proliferation and apoptosis (reviewed in ref. 30 ), but no consistent differences were detected between wild-type and Aim2 -/-mice (Supplementary Fig. 7b ). The NF-kB family of transcription factors is responsible for initiating inflammation and linking inflammation NLRP3, ASC, NLRC4, NLRP6 and caspase-1, against CAC [5] [6] [7] 10, [12] [13] [14] . The mice were assessed for weight loss, survival and clinical scores, which included a semiquantitative assessment of stool consistency and rectal bleeding 7 . The inflammasome-deficient Asc -/-mice showed greater weight loss, morbidity and clinical scores than Aim2 -/-mice ( Fig. 1b-d,  Supplementary Fig. 3a) , as previously reported [5] [6] [7] . Increased disease severity in Asc -/-mice was accompanied by increased infiltration of inflammatory cells (Fig. 1e) and proinflammatory cytokines in the colon [5] [6] [7] . In contrast, disease severity in Aim2 -/-mice was indistinguishable from that in wild-type controls (Fig. 1b-d) . Colon histopathology (blindly scored by a pathologist) revealed no difference in the inflammatory infiltrate between Aim2 -/-and wild-type colons (Fig. 1e,f) . Colonic cytokine mRNA expression ( Fig. 1g) and cytokine production by colon explants (Fig. 1h) were also similar between Aim2 -/-and wild-type mice. We next assessed the status of inflammasome activation during CAC in wild-type as compared to Aim2 -/-mice. Similar protein expression of mature caspase-1 p10 subunit (Fig. 1i, Supplementary Fig. 4a ) and concentrations of IL-1b and IL-18 ( Fig. 1j) were detectable in the colons and colon explants, respectively, from AOM/DSS-treated wild-type and Aim2 -/-mice. In contrast, IL-1b and IL-18 production was lower in Asc -/-colons. Because AIM2 associates with ASC to form an inflammasome 15, 16 , it was somewhat unexpected that the outcomes for Asc -/-and Aim2 -/-mice were distinct. However, intact inflammasome activation in Aim2 -/-mice during CAC is likely due to the presence of other inflammasome-forming sensors, such as NLRP3 and NLRP6, which use ASC as an adaptor molecule and may compensate in the absence of AIM2 (refs. 5-7,11) .
Loss of intestinal barrier integrity promotes intestinal inflammation, and mice deficient in inflammasome components display increased intestinal permeability following the induction of experimental colitis and CAC 5, 6, 10, 13 . However, intestinal permeability was not elevated in AOM/ DSS-treated Aim2 -/-mice compared to wild-type mice ( Supplementary  Fig. 3b ), consistent with a lack of exaggerated inflammation in these mice. Additionally, weight change and colon length did not differ between Aim2 -/-and wild-type mice following induction of acute DSS-induced colitis ( Supplementary Fig. 5a-c) . Moreover, wild-type and Aim2 -/-mice showed similar morbidity and mortality during an extended time course after DSS treatment ( Supplementary Fig. 5d-g ) and produced similar levels of IL-1b and IL-18 after chronic DSS exposure ( Supplementary  Fig. 5h ), suggesting that the inflammasome is intact in Aim2 -/-mice during chronic colitis. As a positive control, IL-1b and IL-18 production was reduced in the colons of Asc -/-mice during chronic colitis ( Supplementary  Fig. 5h ), as previously reported [5] [6] [7] . Finally, we examined another colitis model, which is driven by the transfer of naive CD4 + T cells 25 . The absence of AIM2 in transferred T cells did not alter disease severity ( Supplementary  Fig. 5i-k) . Thus, absence of AIM2 did not affect the severity of colitis in different animal models.
AIM2 protects against precancerous polyp formation in colitisassociated colon cancer
We next examined the impact of AIM2 on colon polyps, a measurement of precancerous growth. High-resolution endoscopy showed that Aim2 -/-mice exposed to AOM/DSS had greater numbers of polyps compared to wild-type mice (Fig. 2a) , and macroscopic polyp counts and tumor load assessments indicated that Aim2 -/-mice had greater numbers of polyps and higher tumor load than Asc -/-and control mice (Fig. 2b,c) . Colon histopathology from Aim2 -/-mice revealed increased crypt dysplasia and hyperplasia compared to wild-type controls (Fig. 2d,e and Supplementary  Fig. 6 ), even though the mice were similar to wild-type animals with respect to inflammatory immune infiltrates in the colon (Fig. 1f) . Thus, Aim2 deficiency resulted in increased hyperplasia, dysplasia and polyps, without attendant increases in inflammation. In contrast, Asc deficiency increased Aim2 -/-mice (Supplementary Fig. 7c ). In addition, activated STAT3, which acts in concert with NF-kB to promote tumorigenesis (reviewed to cancer development (reviewed in ref. 2); however, activation of p65 and IkBa was not elevated in the colons of AOM/DSS-treated wild-type and to Aim2 +/+ controls (Fig. 3d, Supplementary Fig. 4i,j) . This difference in p-Akt was not observed in Asc -/-MEFs (Fig. 3e, Supplementary Fig. 4l ), indicating the different roles of AIM2 and ASC in regulating Akt activation. We confirmed that AIM2 regulated Akt activation in colon cancer or colon epithelial cells through two approaches. First, the human colon carcinoma cell line HCT-116, which lacks functional AIM2 (ref. 19) , was reconstituted by transfection with an AIM2-bearing vector. Akt activation was lower in AIM2-expressing HCT-116 cells than in empty vectortransfected control cells (Fig. 3f, Supplementary Fig. 4m ), indicating that AIM2 reduced Akt activation. Second, primary non-transformed colon epithelial organoid cultures were generated using a combination of growth factors and signaling molecules in a Matrigel system as previously reported (Supplementary Fig. 9 ) [41] [42] [43] . We assessed Akt activation in these threedimensional organoid cultures isolated from wild-type and Aim2 -/-colonic crypts and found increased p-Akt in Aim2 -/-organoids as compared to wild-type control organoids upon IGF-1 stimulation. The basal level of p-Akt was also elevated in Aim2 -/-organoids, likely due to the required exposure of epidermal growth factor for propagation of these primary cells (Fig. 3g, Supplementary Fig. 4n ). These results suggest that AIM2 suppresses Akt activity in non-bone marrow cells, including colonic epithelial cells. In contrast to results from colonic epithelial cells, p-Akt did not differ in wild-type and Aim2 -/-BMDM upon stimulation with LPS or IGF-1 ( Supplementary Fig. 10a,b) . Thus, AIM2 does not affect Akt activation in macrophages, a cell type well characterized as expressing a functional AIM2 inflammasome.
Inhibition of Akt activation in Aim2 -/-mice reduces tumor load in vivo
Consistent with the role of Akt in cell proliferation and survival, staining for Ki-67, a marker of proliferating cells, was increased in colonic crypts from AOM/DSS-treated Aim2 -/-mice (Fig. 4a) . Proliferation was also increased in ref. 31 ), was not elevated in Aim2 -/-mice (Supplementary Fig. 7d) .
We next examined the phosphatidylinositol 3-kinase (PI3K)-Akt pathway of cellular survival because it is frequently mutated in human colorectal cancer 32 . Akt activation occurs through a series of events that involve the phosphorylation of Akt at threonine 308 (Thr308) by the 3-phosphoinositidedependent protein kinase 1 (PDK1) 33 and phosphorylation of serine 473 (Ser473) by the mammalian target of rapamycin (mTOR)-rictor complex 34 . Additionally, DNA-dependent protein kinase (DNA-PK) can directly or indirectly phosphorylate Akt Ser473 (refs. [35] [36] [37] . Activated Akt promotes tumorigenesis by modulating cell cycle progression, apoptosis and cell motility. By contrast, the tumor suppressor phosphatase and tensin homology deleted on chromosome 10 (PTEN) inhibits the actions of PI3K 38 . Because Akt signaling is important in CAC 39 , we assessed Akt activation in Aim2 -/-mice. Similar expression of total Akt (Fig. 3a,b) was found in the colons of wild-type, Aim2 -/-and Asc -/-mice treated with AOM/DSS, but increased Ser473 p-Akt and reduced PTEN were found in Aim2 -/-colons (Fig. 3a, Supplementary Fig. 4b,f) . By contrast, slightly reduced levels of p-Akt were found in Asc -/-colons (Fig. 3b, Supplementary Fig. 4g) . A similar elevation in p-Akt was detected in the colons of Aim2 -/-/Apc Min/+ as compared to Apc Min/+ control mice (Fig. 3c, Supplementary Fig. 4h ), demonstrating that AIM2 regulates Akt activity in models of both CAC and sporadic colon cancer.
We next assessed whether AIM2 can directly regulate Akt in vitro. AIM2 is widely expressed throughout immune tissue and cells 17 ( Supplementary  Fig. 8a ). Human intestinal tissue 17 and colon epithelial cells also express AIM2 (Supplementary Fig. 8b) , and AIM2 mutations are present in colon adenomas and several human colon carcinoma cell lines, implying a role for AIM2 in epithelial cells [18] [19] [20] . To examine Akt activation in vitro, we treated cells with insulin-like growth factor-1 (IGF-1), which activates PI3K and Akt and is elevated in colon cancer 40 . IGF-1-treated Aim2 -/-mouse embryonic fibroblasts (MEFs) had increased Ser473 (but not Thr308) p-Akt compared but not Thr308, hyperphosphorylation in Aim2 -/-MEFs (Fig. 3d) suggests that AIM2 targets an Akt Ser473-specific kinase or phosphatase. Enzymes in the mTOR or DNA-PK pathway are known to phosphorylate Akt at Ser473. Because specific antibodies against endogenous AIM2 are not available, we overexpressed a 3xFLAG-tagged human AIM2 (AIM2-3xFLAG) in HEK293T cells and performed co-immunoprecipitation experiments with endogenous Akt-PI3K components. AIM2 did not associate with Akt, IGF1 receptor (IGF1R), IRS1, IRS2, PI3K, PDK1, mTOR, ATM, the major PI3K-related phosphatases (that is, PTEN, PP2A and PHLPP) or the PTEN-specific ubiquitin ligase NEDD4 (Fig. 5a) . However, AIM2 did associate with DNA-PK (Fig. 5a) , and this was confirmed with reciprocal co-immunoprecipitations (Fig. 5b) . DNA-PK consists of a 470-kDa catalytic subunit (DNA-PKcs) and two 73-and 80-kDa DNA-binding subunits (Ku70 and Ku80) 45 , and DNA-PK can promote cellular survival via Akt activation 35, 37 . Elevated DNA-PK activity and expression has been reported in colorectal tumors 46 , and DNA-PK promotes c-Myc oncoprotein stability 47 . As both AIM2 and DNA-PK bind DNA, their interaction could be a consequence of nonspecific DNA bridging. To address this possibility, immunoprecipitates were treated with the DNA-intercalating agent ethidium bromide (EtBr) to disrupt DNA interactions that could promote indirect associations. The AIM2-DNA-PKcs association was maintained in the presence of EtBr (Fig. 5c) , indicating that this association is not an artifact of their binding to DNA. The AIM2-DNA-PKcs interaction was detected in resting cells, but lost upon IGF-1 stimulation (Fig. 5a,b) , suggesting that the interaction occurred in the resting state but these proteins dissociated from each other upon cellular activation, allowing DNA-PKcs to promote Akt activation. To address this possibility, we tested whether AIM2 could directly in Aim2 -/-MEFs as compared to Aim +/+ controls (Fig. 4b) . Moreover, in Aim2 -/-colons, apoptotic caspase-7 cleavage was lower than in wild-type colons (Fig. 4c, Supplementary Fig. 4o) , and Aim2 -/-MEFs had lower apoptotic caspase-3 cleavage than controls following staurosporine treatment (Fig. 4d, Supplementary Fig. 4p) .
To determine whether activated Akt observed in the absence of AIM2 was required for increased tumorigenesis in Aim2 -/-mice, AOM/DSStreated wild-type and Aim2 -/-mice were given a total of six i.p. injections (corresponding to the end of the second and third rounds of DSS) of a highly specific Akt inhibitor (API-2) previously described to target overactive Akt in cancer cells both in vitro and in vivo 44 . On day 55 of the AOM/DSS model, API-2-treated Aim2 -/-mice had decreased colon polyp numbers, smaller polyps and reduced tumor loads (Fig. 4e,f) as compared to vehicle-treated Aim2 -/-mice following AOM/DSS exposure. API-2 treatment did not reduce tumorigenesis in AOM/DSS-treated wild-type mice (Fig. 4f) , which showed low numbers of colon polyps and little to no detectable p-Akt (shown earlier in Fig. 3a) . These results suggest activated Akt promotes tumorigenesis in Aim2 -/-mice, and AIM2 likely restricts tumorigenesis via limiting Akt activation.
AIM2 interacts with DNA-PK to regulate Akt activation Akt signaling is controlled by kinases (including insulin receptor substrate-1/2 (IRS1/2), PI3K, 3-phosphoinositide dependent protein kinase-1 (PDK1), mTOR and DNA-PK) and phosphatases (including PTEN, protein phosphatase 2A (PP2A) and PH domain leucine-rich repeat protein phosphatase (PHLPP)) that are often hyperactive or inactivated, respectively, in cancer 32 . To further explore the mechanism by which AIM2 inhibits Akt activation, we examined whether AIM2 interacts with these kinases/phosphatases. The presence of p-Akt Ser473, Error bars denote standard error. ns, not significant; *P < 0.05, **P < 0.01, ***P < 0.001; a,b, unpaired t-test; f, Mann-Whitney U-test (due to the non-normal distribution of the data sets and small sample size).
a master regulator of cellular survival often overexpressed in multiple human cancers. AIM2 in resting cells physically associates with and limits activation of DNA-PK, a PI3K-related family member that promotes Akt. Conversely, loss of AIM2 promotes DNA-PK-mediated Akt hyperactivation, thereby promoting proliferation and reducing apoptosis, two hallmarks of cancer development.
AIM2 mutations are found in human tumors 18, 19 , reduced AIM2 expression has been associated with poor prognosis in patients 20 and AIM2 suppresses proliferation [21] [22] [23] . Our findings indicate that loss of AIM2 results in activation of Akt, and suppression of Akt can reduce tumorigenesis in Aim2-deficeint animals. Thus, pharmacological targeting of Akt may be beneficial in individuals with AIM2-deficent tumors. This work implicates AIM2 as having a previously unrecognized role in the dual regulation of innate immune networks and signaling pathways that are critical to cellular survival and tumorigenesis. Although this study focused on colorectal cancer models, loss or mutations in APC in mice are also associated with intestinal tumorigenesis 27, 28 . Furthermore, AIM2 is implicated in human melanoma 17 , and thus further work is needed to investigate whether targeting Akt is beneficial in other cancers associated with AIM2 deficiency.
METHODS
Methods and any associated references are available in the online version of the paper. prevent DNA-PK activation by using AIM2-complemented HCT-116 cells treated with bleocin, which induces potent DNA-PK phosphorylation 45 . Indeed, AIM2 overexpression decreased phosphorylation of DNA-PK (p-DNA-PK; Fig. 5d, Supplementary Fig. 4q ), demonstrating that AIM2 can limit DNA-PK activation. To assess the link between AIM2, DNA-PK and Akt activation, we tested two highly-specific DNA-PKcs inhibitors, NU7026 and NU7441 (ref. 48) , in Aim2 -/-and control cells. Akt Ser473 phosphorylation was higher in IGF-1-treated Aim2 -/-cells as compared to IGF-1-treated wild-type controls, but this difference was not observed with either NU7026 or NU7441 treatment (Fig. 5e, Supplementary  Fig. 4r) . Additionally, p-Akt activation is known to have prosurvival effects. Reduced apoptosis and increased viability in Aim2 -/-cells as compared to wild-type cells was reversed by DNA-PK inhibitors (Fig. 5f,  Supplementary Fig. 4s and Fig. 5g) . These results suggest DNA-PK is required for elevated Akt activation in Aim2 -/-cells.
DISCUSSION
The innate immune DNA sensor AIM2 has been implicated as a potential tumor suppressor, although the mechanism for this effect remained unclear. Here, we assessed the role of the AIM2 inflammasome in the regulation of CAC, but instead found that AIM2 attenuates tumorigenesis through a mechanism independent of inflammasome activation and inflammation. In colon epithelial cells, AIM2 limits the activation of Akt, DNA-PKcs inhibitors. When indicated, MEFs were pre-treated for 30 min or 1 h with the indicated concentration of the DNA-PKcs inhibitors NU7026 (Cayman Chemical) or NU7441 (Tocris), or cultured with a single dose of NU7026 for proliferation assays.
Flow cytometry. Spleen, thymus and inguinal lymph nodes were isolated from naive Aim2 +/+ , Aim2 +/-and Aim2 -/-animals; tissue was gently dissociated and passed through a 70-mm cell strainer to generate single cell suspension; and red blood cells were lysed using ACK buffer. Cells were counted and stained using the following antibodies: anti-CD11b-FITC (cat . no. 11-0112, used at 1:200), anti-CD4-PerCpCy5.5 (cat. no. 45-0042, used at 1:80), anti-CD8-eFluor 450 (cat. no. 48-0083, used at 1:80), anti-CD11c-APC (cat. no. 17-0114, used at 1:80), antiTCRb-Alexa 700 (cat. no. 47-5961, used at 1:80), anti-F480-PE (cat. no. 12-4801, used at 1:80), anti-NK1.1-PECy7 (cat. no. 25-5941, used at 1:80) (eBioscience) and anti-B220-APC Cy7 (cat. no. 565371, used at 1:200) (BD Biosciences). Peripheral blood lymphocytes isolated from radiation bone marrow chimeric mice were stained with anti-CD45.1-PE (BD Biosciences, cat. no. 553776, used at 1:1,000) and anti-CD45.2-V500 (BD Biosciences, cat. no. 562130, used at 1:1,000). Flow cytometry was performed using an LSRII (BD Biosciences), and the resulting data were analyzed using FlowJo (TreeStar).
Statistical analysis. All results are presented as the mean ± s.e.m. (SEM). Significance between two groups was assessed by the Student's two-tailed t-test. The non-parametric Mann-Whitney U-test was used to assess significance between two means of data sets lacking a normal distribution and having a small sample size. Data sets consisting of more than 2 groups were analyzed by analysis of variance (ANOVA) with Tukey-Kramer HSD post test for multiple comparisons if significance was determined. The product limit method of Kaplan and Meier was used for generating the survival curves, which were compared by using the log-rank test. A P value that was less than 0.05 was considered statistically significant for all data sets. All statistical analysis was performed using GraphPad Prism software. Samples that were greater than 3 s.d. from the mean were excluded as outliers.
